No Data
Is The Market Rewarding Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Aotecarbio (688606.SH): Completion of the fundraising project and use of the remaining funds to permanently supplement the company's working capital.
On July 19th, Gelunhui announced that Otaibio (688606.SH) held its 3rd Board of Directors and 3rd Supervisory Board 5th meeting on July 19th, 2024. The Proposal on "Partially closing the raised investment projects and using the remaining funds to supplement the permanent working capital" was deliberated and approved. The company agreed to invest the raised funds in the projects "New industrialized technology upgrade project for the annual production of 0.265 billion people's diagnostic reagents" and "IVD R&D Center Construction Project" (referred to as the "raised investment projects") and use the remaining raised funds to supplement the company's permanent working capital.
Aotec Biology (688606.SH) will distribute a dividend of 1.5 yuan per share for the year 2023, with a registration date of June 19th.
Otaibiology (688606.SH) announced that the company will implement annual equity distribution in 2023, distributing per share...
Lacklustre Performance Is Driving Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) 25% Price Drop
Aotai Biotech (688606.SH): Proposed 1.3 Million Restricted Stock Incentive Plan
Gelonghui, May 14 | Aotai Biotech (688606.SH) announced the 2024 restricted stock incentive plan. The company plans to grant 1.3 million restricted shares to incentive recipients, accounting for about 1.64% of the company's total share capital of 79.280855 million shares when the draft incentive plan was announced. Among them, 1.19 million shares were granted for the first time, accounting for about 1.50% of the company's total share capital at the time the draft incentive plan was announced, accounting for about 91.54% of the total equity granted; 110 million shares were reserved, accounting for about 0.14% of the company's total share capital when the draft incentive plan was announced, accounting for about 0.14% of the company's total share capital at the time the draft incentive plan was announced, accounting for about
Some Investors May Be Worried About Hangzhou Alltest Biotech's (SHSE:688606) Returns On Capital
Is Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Stock Price Struggling As A Result Of Its Mixed Financials?No Data
